Gossamer Bio (NASDAQ:GOSS) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Gossamer Bio (NASDAQ:GOSS) announced its quarterly earnings results on Friday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03), FiscalAI reports. The company had revenue of $16.96 million for the quarter, compared to analysts’ expectations of $4.67 million.

Gossamer Bio Stock Performance

GOSS stock traded up $0.01 during trading on Friday, reaching $0.34. 5,500,862 shares of the company were exchanged, compared to its average volume of 12,326,179. The company has a market cap of $79.80 million, a P/E ratio of -0.45 and a beta of 2.15. Gossamer Bio has a 52-week low of $0.31 and a 52-week high of $3.87. The stock’s 50 day moving average price is $0.40 and its 200 day moving average price is $1.84.

Key Stories Impacting Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Negative Sentiment: Multiple law firms filed or publicized securities class-action claims against Gossamer Bio over allegations tied to the failed PROSERA study, highlighting legal overhang and potential damages risk for shareholders. Article: Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens Berman
• Negative Sentiment: Law firms including Schall, Pomerantz, Rosen, Gross, Faruqi & Faruqi, and Bronstein are urging investors to join or lead the lawsuit, reinforcing concerns that the stock faces ongoing litigation risk and distraction. Article: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
• Neutral Sentiment: Gossamer Bio said it will report first-quarter 2026 financial results and host a conference call on May 18, which may provide new guidance on cash runway, pipeline priorities, and management’s response to the trial setback. Article: Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Institutional Trading of Gossamer Bio

A number of institutional investors have recently added to or reduced their stakes in GOSS. Deutsche Bank AG raised its position in Gossamer Bio by 0.4% during the fourth quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock worth $3,981,000 after acquiring an additional 5,414 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in Gossamer Bio by 52.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after acquiring an additional 8,239 shares during the last quarter. Cerity Partners LLC raised its position in Gossamer Bio by 39.7% during the fourth quarter. Cerity Partners LLC now owns 31,914 shares of the company’s stock worth $99,000 after acquiring an additional 9,075 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new position in Gossamer Bio during the fourth quarter worth about $34,000. Finally, Ieq Capital LLC acquired a new position in Gossamer Bio during the fourth quarter worth about $35,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GOSS shares. The Goldman Sachs Group lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Wedbush restated a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. Barclays downgraded shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th. Finally, Leerink Partners downgraded shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.43.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.